Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Significant Growth in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 319,800 shares, an increase of 1,284.4% from the March 15th total of 23,100 shares. Based on an average daily trading volume, of 386,500 shares, the days-to-cover ratio is currently 0.8 days. Currently, 26.2% of the company’s stock are sold short.

Virpax Pharmaceuticals Trading Down 16.7 %

Shares of NASDAQ VRPX traded down $0.04 during trading hours on Monday, hitting $0.20. The stock had a trading volume of 11,274 shares, compared to its average volume of 200,536. The firm’s 50-day moving average price is $3.99 and its two-hundred day moving average price is $9.18. Virpax Pharmaceuticals has a 52 week low of $0.13 and a 52 week high of $101.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC acquired a new position in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned approximately 1.17% of Virpax Pharmaceuticals at the end of the most recent quarter. Institutional investors own 32.23% of the company’s stock.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.